Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Inoculation of Shake Flasks – V 2.0

Posted on By


Biosimilars: SOP for Inoculation of Shake Flasks – V 2.0


Standard Operating Procedure for Inoculation of Shake Flasks in Biosimilar Upstream Processing

Department Biosimilars
SOP No. SOP/BS/065/2025
Supersedes SOP/BS/065/2022
Page No. Page 1 of 11
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To outline the procedure for aseptic inoculation of shake flasks in biosimilar upstream processing to ensure optimal cell growth and contamination-free seed train scale-up.

2. Scope

This SOP applies to the inoculation of 125 mL, 250 mL, 500 mL, and 1L shake flasks used for scaling up seed cultures from cryopreserved or revived cell banks during biosimilar production.

3. Responsibilities

  • Upstream Technician: Perform inoculation and record batch details.
  • QA Personnel: Review logbooks, monitor environmental controls, and approve culture use.
  • Microbiology Team: Conduct sterility checks on inoculated flasks and air samples.

4. Accountability

The Head of Upstream Process is accountable for ensuring the integrity of inoculated shake flasks and compliance with cGMP procedures for culture scale-up.

5. Procedure

5.1 Preparation Before Inoculation

  1. Verify readiness of seed culture (VCD ≥ 0.5 × 10⁶ cells/mL; viability ≥ 90%).
  2. Label shake flasks with media type, volume, batch ID, and inoculation date (Annexure-1).
  3. Ensure laminar air flow (LAF) cabinet is sterilized and validated before inoculation.

5.2 Flask Selection and Media Transfer

  1. Select sterile Erlenmeyer flasks of appropriate capacity (125 mL–1 L).
  2. Transfer pre-sterilized chemically defined media (CDM) to each flask under LAF conditions using sterile pipettes or transfer tubes.
  3. Fill flasks to 20–30% of total volume to allow adequate aeration.

5.3 Inoculation Procedure

  1. Mix the seed culture gently and aseptically withdraw the required volume.
  2. Inoculate each flask with calculated volume to achieve initial VCD of 0.2–0.5 × 10⁶ cells/mL.
  3. Close flask cap or cotton plug securely and place on sterile tray for transport.

5.4 Incubation and Monitoring

  1. Incubate shake flasks in a rotary shaker at 120–150 rpm, 37°C, and 5% CO₂.
  2. Record environmental parameters and flask placement (Annexure-2).
  3. Monitor VCD, viability, and morphology daily until the desired expansion is reached.

5.5 Contamination Control

  1. Submit air samples and flask surface swabs to microbiology as per SOP/BS/043/2025.
  2. Discard any contaminated flasks immediately as per SOP/BS/048/2025 and record in Deviation Log (Annexure-3).

6. Abbreviations

  • VCD: Viable Cell Density
  • CDM: Chemically Defined Media
  • LAF: Laminar Air Flow
  • RPM: Revolutions Per Minute

7. Documents

  1. Shake Flask Label Record – Annexure-1
  2. Incubation Log Sheet – Annexure-2
  3. Deviation Log for Flask Contamination – Annexure-3

8. References

  • ICH Q7 – GMP for Active Pharmaceutical Ingredients
  • WHO TRS 999 – Guidelines on Biotherapeutic Products
  • SOP/BS/043/2025 – Microbial Monitoring
  • SOP/BS/048/2025 – Biohazardous Waste Disposal

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Shake Flask Label Record

Flask ID Media Type Volume (mL) Inoculation Date Batch ID
FLK-001 CD CHO 250 04/05/2025 SD-CHO-105

Annexure-2: Incubation Log Sheet

Date Temperature (°C) CO₂ (%) RPM Operator
04/05/2025 37.0 5.0 130 Ajay Verma

Annexure-3: Deviation Log for Flask Contamination

Date Flask ID Issue Observed Action Taken Reported By
04/05/2025 FLK-004 Turbidity with fungal growth Discarded Sunita Reddy

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Included incubation control points and contamination log format Process Optimization
See also  Biosimilars: SOP for Cryopreservation of Cell Banks - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: BA-BE Studies: SOP for Emergency Medical Resuscitation Kit Use – V 2.0
Next Post: Aerosol: SOP for Periodic Requalification of Utility Systems – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version